

Miney Paquette

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2988482/publications.pdf>

Version: 2024-02-01

14
papers

644
citations

933447

10
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

1382
citing authors

#	ARTICLE	IF	CITATIONS
1	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	2.8	244
2	Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. <i>American Journal of Medicine</i> , 2015, 128, 1306-1313.e1.	1.5	135
3	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2376-2388.	3.4	84
4	Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. <i>American Heart Journal</i> , 2018, 198, 55-63.	2.7	40
5	Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1573-1583.	2.8	39
6	Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. <i>American Journal of Medicine</i> , 2018, 131, 945-955.e3.	1.5	27
7	Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. <i>American Journal of Cardiology</i> , 2020, 125, 383-391.	1.6	19
8	Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program. <i>American Heart Journal</i> , 2019, 218, 123-127.	2.7	18
9	A meta-epidemiological study of subgroup analyses in cochrane systematic reviews of atrial fibrillation. <i>Systematic Reviews</i> , 2019, 8, 241.	5.3	13
10	Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. <i>Journal of Clinical Medicine</i> , 2020, 9, 1969.	2.4	11
11	Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. <i>Europace</i> , 2019, 22, 47-57.	1.7	10
12	Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 251-260.	3.0	2
13	Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF. <i>TH Open</i> , 2021, 05, e35-e42.	1.4	1
14	Systematic review of treatment gaps in oral anticoagulant use in atrial fibrillation. <i>Thrombosis Update</i> , 2021, 4, 100053.	0.9	1